Medical device company Biocomposites is set to commence UK distribution of its NanoBone product range.

The range includes NanoBone SBX Putty and NanoBone QD, the next-generation synthetic bone grafts designed for early osteogenesis and bone formation.

NanoBone's patented technology features nanostructured hydroxyapatite within a silica gel matrix, suspended in a hydrogel / polymer silica carrier.

This composition supports bone regeneration, offering a healing rate comparable to autografts and osteoinductive properties, without the associated costs and harvesting complications.

The products are preloaded and ready to use, providing surgeons with flexibility and efficiency for various applications.

Biocomposites managing director Dr Walter Gerike said: “NanoBone is a proven technology that has already helped over 100,000 patients throughout the world.

“The UK is a significant market and we are very pleased to start selling our innovative range of ready-to-use products there. This development furthers Biocomposites' position as the go-to provider for surgeons requiring advanced bone regeneration materials.”

The company will unveil the product range at the British Orthopaedic Association’s Annual Congress 2024 in Birmingham, UK.

Last year, Biocomposites acquired German company Artoss, adding the latter’s NanoBone range to its portfolio.

Artoss is a manufacturer of bone graft substitutes for use in orthopaedics, spine, foot and ankle, and dentistry.

With the acquisition, Artoss offers its NanoBone technology and products such as SBX Putty to Biocomposites global distribution network allowing them to reach surgeons and patients in more than 40 countries.

Biocomposites is engaged in engineering, manufacturing and marketing products for use in infection management in bone and soft tissue.

The UK-based company has operations across Europe, South America, Canada, the US, China and India.